| review article | Q7318358 |
| scholarly article | Q13442814 |
| P50 | author | Adriana Castello Costa Girardi | Q74599382 |
| P2093 | author name string | Leonardo dos Santos | |
| Thiago A Salles | |||
| Valério G Barauna | |||
| P2860 | cites work | Endothelial catabolism of extracellular adenosine during hypoxia: the role of surface adenosine deaminase and CD26 | Q24323818 |
| Targeting inflammation in diabetes: Newer therapeutic options | Q26852726 | ||
| Regulation of fibroblast migration on collagenous matrix by a cell surface peptidase complex | Q28218749 | ||
| Neuropeptide Y induces migration, proliferation, and tube formation of endothelial cells bimodally via Y1, Y2, and Y5 receptors | Q28256173 | ||
| Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus | Q28297680 | ||
| Alogliptin after acute coronary syndrome in patients with type 2 diabetes | Q28297690 | ||
| Saxagliptin, alogliptin, and cardiovascular outcomes | Q28306999 | ||
| Human atrial natriuretic peptide: plasma levels, hemodynamic, hormonal, and renal effects in patients with severe congestive heart failure | Q28337760 | ||
| Sitagliptin reduces cardiac apoptosis, hypertrophy and fibrosis primarily by insulin-dependent mechanisms in experimental type-II diabetes. Potential roles of GLP-1 isoforms | Q28535415 | ||
| The cysteine-rich region of dipeptidyl peptidase IV (CD 26) is the collagen-binding site | Q28578376 | ||
| Effects of DPP-4 inhibitors on the heart in a rat model of uremic cardiomyopathy | Q28742534 | ||
| Dysregulation of microRNAs after myocardial infarction reveals a role of miR-29 in cardiac fibrosis | Q29619873 | ||
| 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines | Q29620107 | ||
| Protection of glucagon-like peptide-1 in cisplatin-induced renal injury elucidates gut-kidney connection. | Q30390165 | ||
| Vasoactive intestinal peptide: cardiovascular effects | Q31718400 | ||
| Genetic deletion or pharmacological inhibition of dipeptidyl peptidase-4 improves cardiovascular outcomes after myocardial infarction in mice | Q33750640 | ||
| Protease-resistant stromal cell-derived factor-1 for the treatment of experimental peripheral artery disease. | Q33845786 | ||
| Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus | Q45306841 | ||
| Glucagon-like peptide-1 (GLP-1): effect on kidney hemodynamics and renin-angiotensin-aldosterone system in healthy men. | Q45730273 | ||
| Dipeptidyl peptidase 4 inhibition increases myocardial glucose uptake in nonischemic cardiomyopathy | Q46095695 | ||
| Elevation of plasma neuropeptide Y levels in congestive heart failure | Q46725763 | ||
| Dipeptidyl-peptidase IV converts intact B-type natriuretic peptide into its des-SerPro form | Q46778176 | ||
| Dipeptidyl peptidase IV inhibition downregulates Na+ - H+ exchanger NHE3 in rat renal proximal tubule. | Q46852265 | ||
| Impact of acute hyperglycemia on myocardial infarct size, area at risk, and salvage in patients with STEMI and the association with exenatide treatment: results from a randomized study | Q47180985 | ||
| Renal and intestinal absorptive defects in mice lacking the NHE3 Na+/H+ exchanger | Q47852356 | ||
| Circulating dipeptidyl peptidase IV activity correlates with cardiac dysfunction in human and experimental heart failure. | Q47914982 | ||
| Increased plasma levels of brain natriuretic peptide in patients with acute myocardial infarction | Q48259434 | ||
| Renal effects of brain natriuretic peptide in patients with congestive heart failure | Q48326773 | ||
| Des-serine-proline brain natriuretic peptide 3-32 in cardiorenal regulation | Q48386405 | ||
| Glucagon-like peptide-1 is involved in sodium and water homeostasis in humans | Q48440967 | ||
| Brain natriuretic peptide administered to man: actions and metabolism | Q49042771 | ||
| Effect of heart failure on dipeptidyl peptidase IV activity in plasma of dogs | Q49179704 | ||
| Bully for Science! The FASEB Centennial (1912-2012). | Q50094550 | ||
| Serum levels of advanced glycation end products (AGEs) are independently correlated with circulating levels of dipeptidyl peptidase-4 (DPP-4) in humans. | Q51290529 | ||
| Increased plasma dipeptidyl peptidase 4 activities predict new-onset microalbuminuria in association with its proinflammatory effects in Chinese without diabetes: a four-year prospective study. | Q51314588 | ||
| Higher serum DPP-4 enzyme activity and decreased lymphocyte CD26 expression in type 1 diabetes. | Q51370364 | ||
| Shedding of dipeptidyl peptidase 4 is mediated by metalloproteases and up-regulated by hypoxia in human adipocytes and smooth muscle cells. | Q51697808 | ||
| Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. | Q52951285 | ||
| Stromal cell-derived factor-1 retention and cardioprotection for ischemic myocardium. | Q53245923 | ||
| Local delivery of protease-resistant stromal cell derived factor-1 for stem cell recruitment after myocardial infarction. | Q53527159 | ||
| Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. | Q53886146 | ||
| Mechanisms mediating the diuretic and natriuretic actions of the incretin hormone glucagon-like peptide-1. | Q54588963 | ||
| Cardioprotection by ischemic postconditioning is lost in isolated perfused heart from diabetic rats: Involvement of transient receptor potential vanilloid 1, calcitonin gene-related peptide and substance P. | Q54591392 | ||
| Dipeptidyl peptidase IV inhibition improves cardiorenal function in overpacing-induced heart failure | Q57097937 | ||
| Renal effects of glucagon-like peptide in rats | Q57218990 | ||
| Molecular characterization of dipeptidyl peptidase activity in serum | Q62660688 | ||
| Expression of dipeptidyl peptidase IV in rat tissues is mainly regulated at the mRNA levels | Q69369450 | ||
| Effects of brain natriuretic peptide on renal nerve activity in conscious rabbits | Q69960096 | ||
| The role of substance P in myocardial dysfunction during ischemia and reperfusion | Q71816612 | ||
| Purification and characterization of an aminopeptidase hydrolyzing glycyl-proline-naphthylamide | Q71870605 | ||
| Stimulation of the expression and the enzyme activity of aminopeptidase N/CD13 and dipeptidylpeptidase IV/CD26 on human renal cell carcinoma cells and renal tubular epithelial cells by T cell-derived cytokines, such as IL-4 and IL-13 | Q72220458 | ||
| Interferon-gamma induces dipeptidylpeptidase IV expression in human glomerular epithelial cells | Q72664503 | ||
| Proteolytic processing of neuropeptide Y and peptide YY by dipeptidyl peptidase IV | Q72671843 | ||
| Interleukin-12 enhances CD26 expression and dipeptidyl peptidase IV function on human activated lymphocytes | Q73980584 | ||
| Association of Na(+)-H(+) exchanger isoform NHE3 and dipeptidyl peptidase IV in the renal proximal tubule | Q74599385 | ||
| Pathophysiology of sodium and water retention in heart failure | Q77531997 | ||
| Regulation of endothelial cell branching morphogenesis by endogenous chemokine stromal-derived factor-1 | Q77869788 | ||
| The incidence of congestive heart failure in type 2 diabetes: an update | Q80384667 | ||
| Increased NHE3 abundance and transport activity in renal proximal tubule of rats with heart failure | Q82228645 | ||
| Serum DPPIV activity and CD26 expression on lymphocytes in patients with benign or malignant breast tumors | Q83332373 | ||
| Comparison of mass spectrometry and clinical assay measurements of circulating fragments of B-type natriuretic peptide in patients with chronic heart failure | Q83366366 | ||
| Dual stem cell therapy after myocardial infarction acts specifically by enhanced homing via the SDF-1/CXCR4 axis | Q84552881 | ||
| Effects of sitagliptin therapy on markers of low-grade inflammation and cell adhesion molecules in patients with type 2 diabetes | Q87407865 | ||
| Dipeptidyl peptidase-4 modulates left ventricular dysfunction in chronic heart failure via angiogenesis-dependent and -independent actions | Q87408607 | ||
| Dipeptidyl peptidase IV inhibition upregulates GLUT4 translocation and expression in heart and skeletal muscle of spontaneously hypertensive rats | Q87422267 | ||
| Expression of MicroRNA-29 and Collagen in Cardiac Muscle after Swimming Training in Myocardial-Infarcted Rats | Q87467869 | ||
| Dipeptidyl peptidase-4 inhibition improves left ventricular function in chronic kidney disease | Q88013961 | ||
| Comparison of nephron-protective effects of enalapril and GLP analogues (exenatide) in diabetic nephropathy | Q88103886 | ||
| Effect of vasoactive intestinal peptide on isolated perfused rat kidney | Q93642461 | ||
| The oral dipeptidyl peptidase-4 inhibitor sitagliptin increases circulating endothelial progenitor cells in patients with type 2 diabetes: possible role of stromal-derived factor-1alpha. | Q33932817 | ||
| Dipeptidyl peptidase inhibition prevents diastolic dysfunction and reduces myocardial fibrosis in a mouse model of Western diet induced obesity | Q34027687 | ||
| Stromal cell-derived factor 1 as a biomarker of heart failure and mortality risk. | Q34081629 | ||
| Kinetic study of the processing by dipeptidyl-peptidase IV/CD26 of neuropeptides involved in pancreatic insulin secretion. | Q34100605 | ||
| Molecular forms of human brain natriuretic peptide in plasma | Q34105689 | ||
| Quantitative mass spectral evidence for the absence of circulating brain natriuretic peptide (BNP-32) in severe human heart failure | Q34161199 | ||
| Pathophysiology of chronic heart failure | Q34239875 | ||
| GLP-1 receptor activation and Epac2 link atrial natriuretic peptide secretion to control of blood pressure | Q34336097 | ||
| Stimulation of glucagon-like peptide-1 receptor through exendin-4 preserves myocardial performance and prevents cardiac remodeling in infarcted myocardium | Q34355984 | ||
| Exendin-4 and sitagliptin protect kidney from ischemia-reperfusion injury through suppressing oxidative stress and inflammatory reaction | Q34508051 | ||
| Evidence for a role of dipeptidyl peptidase IV in fibronectin-mediated interactions of hepatocytes with extracellular matrix. | Q34668282 | ||
| Lung endothelial dipeptidyl peptidase IV promotes adhesion and metastasis of rat breast cancer cells via tumor cell surface-associated fibronectin | Q34751948 | ||
| Neuropeptide Y and its receptors as potential therapeutic drug targets | Q34989362 | ||
| Dipeptidyl peptidase 4 is a novel adipokine potentially linking obesity to the metabolic syndrome | Q35063234 | ||
| Neuropeptide Y: a novel mechanism for ischemic angiogenesis | Q35066249 | ||
| Enhancement of antigen-induced T-cell proliferation by soluble CD26/dipeptidyl peptidase IV. | Q35154326 | ||
| Dipeptidyl-peptidase IV from bench to bedside: an update on structural properties, functions, and clinical aspects of the enzyme DPP IV. | Q35189265 | ||
| Mechanisms of renal hyporesponsiveness to ANP in heart failure | Q35202136 | ||
| Effects of L- and D-arginine on the basal tone of human diseased coronary arteries and their responses to substance P. | Q35372033 | ||
| Substance P in heart failure: the good and the bad. | Q35670008 | ||
| Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. | Q35809679 | ||
| Cardioprotective role of the VIP signaling system | Q36296184 | ||
| Natriuretic effect by exendin-4, but not the DPP-4 inhibitor alogliptin, is mediated via the GLP-1 receptor and preserved in obese type 2 diabetic mice | Q36312680 | ||
| Glucagon-like peptide-1 receptor stimulation increases GFR and suppresses proximal reabsorption in the rat. | Q36527908 | ||
| Biologic actions and therapeutic potential of the proglucagon-derived peptides | Q36575421 | ||
| Induction of the 2B9 antigen/dipeptidyl peptidase IV/CD26 on human natural killer cells by IL-2, IL-12 or IL-15. | Q36868264 | ||
| Role of CD26/dipeptidyl peptidase IV in human T cell activation and function | Q36992436 | ||
| Chronic glucagon-like peptide-1 infusion sustains left ventricular systolic function and prolongs survival in the spontaneously hypertensive, heart failure-prone rat. | Q37322877 | ||
| Adipose dipeptidyl peptidase-4 and obesity: correlation with insulin resistance and depot-specific release from adipose tissue in vivo and in vitro | Q37331331 | ||
| On the origin of serum CD26 and its altered concentration in cancer patients. | Q37532070 | ||
| Role of the SDF-1/CXCR4 system in myocardial infarction | Q37684667 | ||
| Remodeling in the ischemic heart: the stepwise progression for heart failure. | Q37914737 | ||
| Cellular mechanisms for diastolic dysfunction in the human heart | Q37978955 | ||
| Receptor for advanced glycation end products (RAGE) and implications for the pathophysiology of heart failure | Q37997993 | ||
| Deciphering the mechanisms of the Na+/H+ exchanger-3 regulation in organ dysfunction. | Q37998392 | ||
| A general theory of acute and chronic heart failure | Q38000729 | ||
| Dipeptidyl peptidase 4 as a therapeutic target in ischemia/reperfusion injury. | Q38031093 | ||
| Role of GLP-1 and DPP-4 in diabetic nephropathy and cardiovascular disease | Q38042110 | ||
| Natriuretic peptides in cardiovascular diseases: current use and perspectives | Q38162429 | ||
| Cardiovascular actions of GLP-1 and incretin-based pharmacotherapy. | Q38199984 | ||
| Glucagon-like peptide-1 receptor agonists for the treatment of type 2 diabetes: differences and similarities. | Q38201586 | ||
| The CXCL12/CXCR4 chemokine ligand/receptor axis in cardiovascular disease | Q38223391 | ||
| The potential for renoprotection with incretin-based drugs | Q38227648 | ||
| A review of gliptins for 2014. | Q38266290 | ||
| Protective Effects of Glucagon-like Peptide 1 on Endothelial Function in Hypertension | Q38266576 | ||
| DPP-4 inhibition by sitagliptin improves the myocardial response to dobutamine stress and mitigates stunning in a pilot study of patients with coronary artery disease | Q38376373 | ||
| Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial | Q38424163 | ||
| Natriuretic peptide-based screening and collaborative care for heart failure: the STOP-HF randomized trial | Q38448978 | ||
| Early and late effects of the DPP-4 inhibitor vildagliptin in a rat model of post-myocardial infarction heart failure | Q38787227 | ||
| Linagliptin-mediated DPP-4 inhibition ameliorates kidney fibrosis in streptozotocin-induced diabetic mice by inhibiting endothelial-to-mesenchymal transition in a therapeutic regimen | Q39020537 | ||
| Plasma neuropeptide Y on admission to a coronary care unit: raised levels in patients with left heart failure | Q39235319 | ||
| Vasoactive intestinal peptide induces oxidative stress and suppresses metastatic potential in human clear cell renal cell carcinoma | Q39249967 | ||
| Unchanged signaling capacity of mutant CD26/dipeptidylpeptidase IV molecules devoid of enzymatic activity. | Q39488022 | ||
| Antiapoptotic effects of GLP-1 in murine HL-1 cardiomyocytes | Q39600857 | ||
| Expression and spatial heterogeneity of dipeptidyl peptidases in endothelial cells of conduct vessels and capillaries. | Q39613724 | ||
| Synergy between CD26/DPP-IV inhibition and G-CSF improves cardiac function after acute myocardial infarction. | Q39990285 | ||
| Dipeptidyl peptidase IV and mortality after an acute heart failure episode | Q40104342 | ||
| Role of dipeptidyl peptidase IV in regulating activity of Na+/H+ exchanger isoform NHE3 in proximal tubule cells. | Q40542333 | ||
| Atrial natriuretic factor in normal subjects and heart failure patients. Plasma levels and renal, hormonal, and hemodynamic responses to peptide infusion | Q40919655 | ||
| Glucagon-like peptide-1 and the exenatide analogue AC3174 improve cardiac function, cardiac remodeling, and survival in rats with chronic heart failure | Q41267217 | ||
| Dipeptidyl peptidase IV, a kidney brush-border serine peptidase | Q41828139 | ||
| Effect of vildagliptin, a dipeptidyl peptidase 4 inhibitor, on cardiac hypertrophy induced by chronic beta-adrenergic stimulation in rats | Q41873186 | ||
| Glucagon-like peptide-1: effect on pro-atrial natriuretic peptide in healthy males | Q41886690 | ||
| GLP-1R agonist liraglutide activates cytoprotective pathways and improves outcomes after experimental myocardial infarction in mice | Q41984767 | ||
| A collagen-binding glycoprotein on the surface of mouse fibroblasts is identified as dipeptidyl peptidase IV. | Q42134471 | ||
| Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways | Q42165735 | ||
| Migratory activity of circulating progenitor cells and serum SDF-1α predict adverse events in patients with myocardial infarction | Q42439863 | ||
| Neuroendocrine activation after myocardial infarction | Q42578761 | ||
| Advanced glycation end products evoke endothelial cell damage by stimulating soluble dipeptidyl peptidase-4 production and its interaction with mannose 6-phosphate/insulin-like growth factor II receptor. | Q42589786 | ||
| Exenatide reduces infarct size and improves cardiac function in a porcine model of ischemia and reperfusion injury | Q43574002 | ||
| Dipeptidyl peptidase IV inhibition attenuates blood pressure rising in young spontaneously hypertensive rats. | Q43592968 | ||
| Dipeptidyl-peptidase IV inhibition improves pathophysiology of heart failure and increases survival rate in pressure-overloaded mice | Q44319013 | ||
| Brain natriuretic peptide: interaction with renal ANP system | Q44609469 | ||
| Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion | Q44774818 | ||
| Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. | Q44924385 | ||
| Glucagon-like peptide-1 relaxes rat conduit arteries via an endothelium-independent mechanism | Q45176382 | ||
| Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury | Q45199143 | ||
| P275 | copyright license | Creative Commons Attribution | Q6905323 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heart failure | Q181754 |
| pathophysiology | Q1135939 | ||
| enzyme | Q8047 | ||
| P5008 | on focus list of Wikimedia project | ScienceSource | Q55439927 |
| P304 | page(s) | 4226-4249 | |
| P577 | publication date | 2015-02-16 | |
| P1433 | published in | International Journal of Molecular Sciences | Q3153277 |
| P1476 | title | Potential role of dipeptidyl peptidase IV in the pathophysiology of heart failure | |
| P478 | volume | 16 |
| Q64252227 | Cardioprotection Conferred by Sitagliptin Is Associated with Reduced Cardiac Angiotensin II/Angiotensin-(1-7) Balance in Experimental Chronic Kidney Disease |
| Q35979232 | Gastrointestinal Endogenous Protein-Derived Bioactive Peptides: An in Vitro Study of Their Gut Modulatory Potential |
| Q26739999 | Incretin-Based Therapies for Diabetic Complications: Basic Mechanisms and Clinical Evidence |
| Q42876331 | Renoprotective Effects of the Dipeptidyl Peptidase-4 Inhibitor Sitagliptin: A Review in Type 2 Diabetes |
| Q92486237 | Safety, tolerability, pharmacokinetics and pharmacodynamics of parenterally administered dutogliptin: A prospective dose-escalating trial |
| Q88911120 | Sitagliptin reduces inflammation, fibrosis and preserves diastolic function in a rat model of heart failure with preserved ejection fraction |
| Q39751432 | The contributions of dipeptidyl peptidase IV to inflammation in heart failure. |
Search more.